Pharvaris N.V. (PHVS): JMP Securities Sees 210% Price Potential - HAE Treatment for Both Prophylaxis and Acute Emergency

Pharvaris N.V. (PHVS) is a company developing new medications for a rare disease known as hereditary angioedema (HAE). This condition leads to sudden and painful swelling in various parts of the body, such as the face, hands, or even the throat, which can be life-threatening. The uniqueness of Pharvaris lies in its development of Deucrictibant, a tablet that is intended to work as effectively as an injection but is easier to take and better tolerated. Their main drug is called Deucrictibant, and they are testing it in two forms: one for emergencies...